Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden (Q43411786)

23 November 2017

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden (English)

1 reference

23 November 2017

0 references

M Ekman

1

1 reference

23 November 2017

C Bienfait-Beuzon

series ordinal

2

1 reference

23 November 2017

J Jackson

series ordinal

3

1 reference

23 November 2017

17 July 2008

1 reference

Journal of Human Hypertension

23 November 2017

1 reference

23 November 2017

22

1 reference

23 November 2017

12

1 reference

23 November 2017

845-855

1 reference

https://scigraph.springernature.com/pub.10.1038/jhh.2008.76

23 November 2017

0 references

cites work

Essential hypertension: the heart and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

High remaining risk in poorly treated hypertension: the ‘rule of halves’ still exists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Targeting effective blood pressure control with angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Markov models in medical decision making: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Blood Pressure Lowering and Life Expectancy Based on a Markov Model of Cardiovascular Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Cost of heart failure in Swedish primary healthcare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Costs of coronary heart disease and stroke: the case of Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Prevalence of nonfatal coronary heart disease among American adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Incidence and epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Lifetime Risk for Developing Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Stroke incidence and prevalence in Europe: a review of available data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Swedish population health-related quality of life results using the EQ-5D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

A meta-analysis of quality-of-life estimates for stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Angiotensin II antagonists for hypertension: are there differences in efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

The cost of angina pectoris in Sweden.

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Cost of stroke in Sweden: an incidence estimate

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Epidemiology of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Epidemiology of heart failure in Sweden--a national survey

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Establishing health state valuations for disease specific states: an example from heart disease

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.76

7 January 2021

Identifiers

DOI

10.1038/JHH.2008.76

1 reference

Dimensions Publication ID

23 November 2017

0 references

1 reference